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The Smith-Lemli-Opitz syndrome (SLOS), is an autosomal recessive disorder caused by a 7-dehy- 
drocholesterol reductase deficiency, which is characterized by abnormally elevated amniotic fluid 
7-DHC (7-dehydrocholesterol) concentrations. A GC/FID (gas-chromatography with a flame ioni-
zation detector) and GC/MS (gas-chromatography with a mass detector) method was optimized for 
the detection of cholesterol and 7-DHC in amniotic fluids. The quantitative determination of cho-
lesterol in 39 control amniotic fluids evidenced that between the fourth and fifth month of preg-
nancy the levels of this analyte are quite constant, the concentration of total and free cholesterol 
being respectively 10.3 μg·mL−1 (SD = ±3.6) and 1.7 μg·mL−1 (SD = ±0.91), while the analysis of 60 
amniotic fluids potentially related to SLOS, showed a higher variability of cholesterol levels. 
Moreover, in 13 samples an analyte which did not correspond either to cholesterol or to 7-DHC 
was detected. A GC/MS investigation allowed us to identify this compound as lathosterol, a pre-
cursor of cholesterol in the biosynthetic pathway. 
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Cholesterol is an essential lipid which is a precursor for many sterol-based compounds and is involved in the 
regulation of the precise pattering of embryonic structures [1]. Thus, a defeat in its availability during pregnancy 
has severe consequences to the fetus, interfering in its regular development [2].  
Cholesterol is produced from lanosterol through a complex biosynthetic pathway involving several multien- 
zymatic reactions, including demethylations, isomerization, desaturation, and double-bond reductions. Several 
polimalformative disorders [3]-[6] have been identified, deriving from enzyme defects in cholesterol biosynthesis 
[7] [8]. In particular the Smith-Lemli-Opitz syndrome (SLOS), is an autosomal recessive disorder affecting 
1:20000 individuals, characterized by a recognizable pattern of minor facial anomalies, limb abnormalities and 
multiple congenital anomalies including pseudohermaphroditism in males, neonatal hypotonia, mental retardation 
and failure to thrive [9]-[12]. This disease, caused by a 7-dehydrocholesterol reductase deficiency, is characte-
rized by high blood levels of specific metabolites of postsqualene cholesterol biosynthesis [13]. A clinical suspi-
cion of SLOS is usually confirmed by a marked increase of 7-dehydrocholesterol (7-DHC) in plasma or tissues, 
accompanied by decreased levels of cholesterol, which is consistent with a 7-dehydrocholesterol reductase defi-
ciency [14]. The determination of serum cholesterol and 7-DHC by GC/MS is the method of choice for SLOS 
diagnosis [15], even if other analytical approaches have been described [16]-[18] Figure 1. This method was also 
applied to the prenatal diagnosis for the determination of sterols in amniotic fluid [15] [19]-[26]. It was demon-
strated that abnormally elevated amniotic fluid 7-DHC concentrations are an accurate predictor of fetal SLOS [27] 
[28]. In this paper, we describe the results obtained for the determination of free cholesterol, total cholesterol and 
its derivatives in 39 amniotic fluids without genetic alterations, considered as control fluids and in 60 amniotic 
fluids withdrawn from pregnant women, showing a fetal growth retardation potentially related to SLOS, in order 
to confirm the correlation between this pathology and the sterol levels in amniotic fluid.  
The fetal growth retardation were divided into three classes: an overt intra uterine growth retardation (IUGR), 
a smaller fetus respect to the gestational age (SGA) and cases in which further biomedical studies were neces-
sary (ACC). 
In the case of the amniotic fluids related to fetal growth retardations only the quantitative determination of to-
tal cholesterol was carried out, in fact it was not possible to determine its free portion because of the small 
amount of amniotic fluid available after the routine cytogenetic investigations. 
In the screening phase the determinations were carried out by means of the GC/FID technique, which allows a 
fast and accurate quali-quantitative detection of the analytes of interest; the fluids which presented altered con-
centration values of sterols were further investigated by GC/MS, a technique able to detect compounds structu-
rally related to cholesterol, belonging to its biosynthetic pathway. 
2. Experimental 
2.1. Materials 
All reagents and solvents were of analytical-reagent grade. Cholesterol, 7-DHC, lathosterol and stigmasterol 
were purchased from Sigma (St. Louis, MO), cyclohexane was obtained from J.T. Baker (Phillipsburg, NJ), 
ethanol from Carlo Erba (Milano), KOH and pyridine from Merck (Darmstadt), 0.9% NaCl solution from Baxter 
(Trieste). 
Derivatization reagents were N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) with 1% trimethylchloro- 
silano (TMCS) (Supelco inc., Bellafonte). 
 
 
            Figure 1. Chemical structure of cholesterol, 7-dehydrocholesterol, lathosterol.               
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Statistic analysis was carried out by means of ANOVA test, following the ICH rules. 
Standard Solutions 
Stock standard solutions (1 mg·mL−1) of cholesterol, 7-DHC and stigmasterol (internal standard, IS) were pre-
pared in cyclohexane and then diluted in volumetric flasks to concentrations of 50.0, 100.0, 150.0, 200.0, 300.0, 
400.0, 600.0, 800.0 µg·mL−1 for cholesterol; 2.0, 5.0, 7.0, 10.0, 15.0, 20.0, 30.0, 50.0 µg·mL−1 for 7-DHC and 
50.0 µg·mL−1 for IS and stored at 4˚C for up to a month. 
2.2. Standard Samples Preparation 
Aliquots of 0.1 mL of standard solution of cholesterol and 7-DHC, were placed in a 10 mL conical tube and 
cycloexane was evaporated. 1.0 mL of physiologic solution (NaCl 0.9%) and 0.1 mL of the internal standard 
solution (50.0 µg mL−1) were added to the residue. The standard samples underwent the extraction procedure as 
described in paragraph 2.5. 
2.3. Amniotic Fluids (AF) 
39 AF, taken by amniocentesis from women with a normal fetal growth between the 14th and the 21st week of 
pregnancy, were supplied by Laboratorio TOMA; 60 AF, taken by women between the 23th and the 37th week of 
pregnancy showing a retardation in the fetal growth potentially related to SLOS, were obtained from Policlinico 
Nuovo S. Eugenio (University “Tor Vergata” of Rome). The amniotic fluids were stored at +4˚C until analysis. 
Amniotic fluids were withdrawn on the patient’s request to carry out prenatal cytogenetic analysis under cur-
rent Italian law. After cytogenetic analysis on the supernatant the determination of cholesterol and 7-DHC was 
performed. 
2.4. Extraction 
The total amount of cholesterol and 7-DHC were obtained from amniotic fluids by the liquid-liquid extraction 
protocol reported below. 0.5 mL of amniotic fluid samples added with 0.5 mL of physiologic solution were 
placed in a 10 mL glass tube; the mixture was spiked with 0.1 mL of IS (50.0 µg mL−1), saponified for 60 min at 
60˚C with 1 mL 1 M KOH in 90% ethanol and extracted three times with 1 mL cycloexane. The tubes were cen-
trifuged at 7000 rpm for 10 min and the organic phase was isolated. After evaporation of the solvent, the residue 
was derivatized with 100 µL BSTFA + TMCS in pyridine (1:1) at 60˚C for 1 h. The derivatized samples were 
analysed by capillary gas chromatography with a flame ionization detector (CGC/FID) and peak identity was 
confirmed by capillary gas chromatography coupled with a mass spectrometry (CGC/MS). 
Free cholesterol concentrations were obtained following an analogous protocol, omitting the saponification 
procedure. 
2.5. GC/FID Analysis 
Aliquots (2 µL) of the derivatized samples were injected (model 7673 autosampler, Hewlett Packard, Palo Alto, 
CA) into a CGC/FID system consisting in a Hewlett Packard GC (model 5890 series II) equipped with a flame 
ionization detector (FID) and controlled with a Chemstation software. Chromatographic conditions were as fol-
lows: a fused-silica capillary Hewlett Packard column (HP-1, 12 m × 0.20 mm i.d., stationary phase, 0.33 μm 
methyl silicone) was used for separation with helium as the carrier gas (flow rate: 1 mL min−1). The injector and 
detector temperatures were 280˚C and 300˚C respectively and the oven temperature was raised from 200 to 
300˚C at 8˚C/min and held constant for 2.5 min. The total analysis time was 15 min. 1 µL of sample was in-
jected in a spitless mode TMS derivatives of cholesterol and 7-DHC in amniotic fluid samples were identified 
by comparing their retention time with those of the TMS derivatives of the authentic compounds (Sigma). 
2.6. GC/MS Analysis 
The qualitative analyses were performed using an a Hewlett Packard (Palo Alto, CA) model 5890 series II in-
strument equipped with a 7673A automatic injector with electronic pressure control and interfaced to a HP 
5971A mass selective detector. HP Chemstation software was used for data acquisition and processing. GC op-
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erating conditions were as follows: a fused-silica capillary column HP-5 MS (30 m × 0.25-mm i.d., 0.25-μm 
film thickness) was used with helium as the carrier gas (flow rate: 1 mL min−1). The injector and detector tem-
peratures were 280˚C and 300˚C respectively; the oven temperature was raised from 70˚C to 220˚C at 40 ˚C/min 
and then to 320˚C at 10˚C/min and held constant for 2 min. The total analysis time was 15 min. 1 µL of sample 
was injected in a spitless mode. MS was operated in EI mode at 70 eV. For MS mode, full scan spectral acquisi-
tion was run at 1 scan per second and begun at m/z 40 to m/z 550. TMS derivatives of cholesterol and 7-DHC in 
amniotic fluid samples were identified by comparing their retention time and mass spectra with those of the 
TMS derivatives of authentic compounds (Sigma). 
3. Validation 
3.1. Linearity 
Five standard samples at different concentration levels ranging from 5.0 to 80.0 µg mL−1 for cholesterol and 
from 0.2 to 5.0 µg mL−1 for 7-DHC were prepared and checked for linearity. For every solution at different 
concentration five different samples were prepared. The calibration curves were obtained plotting the response 
ratio (area of the analyte/area of the IS) versus the concentration using the least-squares method. The statistic 
pararemeters are reported in Table 1. 
3.2. Precision 
Precision, the degree of agreement among individual test results when the procedure is applied repeatedly to 
multiple samplings, expressed as coefficient of variation (%CV), was evaluated by replicate analyses of samples 
with concentration 15.0, 30.0, 60.0 µg mL−1 for cholesterol and 0.7, 1.5, 3.0 µg mL−1 for 7-DHC. For the in-
tra-day precision the analyses were carried out in one laboratory by one operator, using the same reagents and 
instruments over a relatively short time span. Results are shown in Table 2. Inter-day precision was assessed 
performing two sets of six analyses carried out over different days, verifying that the coefficients of variation of 
each set were not significantly different (ANOVA test). Results are shown in Table 3. 
3.3. Accuracy/Recovery 
The accuracy of the method is defined as the degree of the agreement of test result generated by the method to 
the true value. Accuracy of the method was checked at three concentration levels: 15.0, 30.0, 60.0 mg mL−1 for 
cholesterol and 0.7, 1.5, 3.0 mg mL−1 for 7-DHC. The analytical recovery was used to assess the accuracy and 
the accuracy was determined by evaluating standard samples containing known amounts of cholesterol and 
7-DHC respectively, and using calibration curves to predict concentration value. Results are shown in Table 4. 
3.4. Limits of Detection (LOD) and of Quantitation (LOQ) 
The LOD, defined as the lowest concentration of analyte that can be clearly detected, is estimated as three times 
the signal to noise ratio. The LOD was determined by injecting standard solution of various concentrations. For 
this method, the minimum concentration of cholesterol and 7-DHC that could be detected was 0.02 µg mL−1. The 
LOQ of cholesterol and 7-DHC, (signal to noise ratio of 10/1) was 0.5 and 0.2 µg mL−1, respectively. 
3.5. Stability of Cholesterol in Amniotic Fluids 
Stability of cholesterol in amniotic fluids was evaluated in three different samples taken from women with the 
same age and pregnancy week. The sample were divided into two portions and conserved at 4˚C and 20˚C. The 
total concentration of cholesterol after one, two, seven and fifteen days was determined in each sample as de-
scribed above (Table 5). In the same way in Table 6 the results obtained for the stability of derivatized choles-
terol are reported. 
4. Results and Discussion 
The data obtained in the validation procedure demonstrate that the analytical method is suitable for the 
quali-quantitative determination of cholesterol and 7-DHC in amniotic fluids. In particular the method resulted 
to be easy to apply, linear, accurate, reproducible, repeatable, sensitive and selective (there were no interfering 
V. Gambaro et al. 
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Table 1. Linearity results of cholesterol and 7-DHC.                                                            
Compound Results Value from t-test significance table (α = 0.05) 
Cholesterol   
Linear range (μg·mL−1) 5.0 - 80.0  
n 25  
Slope (b) 0.106  
Intercept (a) −0.016  
Correlation coefficient (r) 0.9997  
CV% 2.3  
Confidence limits of a ±0.234  
t-student −0.14 2.07 
ANOVA test:   
F-test (Regression) 34426 4.35 
F-test (Deviation from linearity) 1.677 3.10 
   
7-DHC   
Linear range (μg·mL−1) 0.2 - 5.0  
n 25  
Slope (b) 0.081  
Intercept (a) 0.021  
Correlation coefficient (r) 0.9988  
CV% 5.1  
Confidence limits of a ±0.020  
t-student 2.04 2.07 
ANOVA test:   
F-test (Regression) 9469 4.35 
F-test (Deviation from linearity) 5.575 3.10 
 
Table 2. Intra-day precision of cholesterol and 7-DHC.                                                          




(mean ± SD) 
n = 6 
CV% Added (µg·mL−1) 
Measured 
(mean ± SD) 
n = 6 
CV% 
15.0 15.5 ± 0.2 1.5 0.7 0.5 ± 0.02 3.8 
30.0 30.9 ± 0.5 1.6 1.5 0.9 ± 0.06 6.7 
60.0 60.6 ± 1.0 1.6 3.0 2.5 ± 0.08 3.5 
 
Table 3. Inter-day precision of cholesterol and 7-DHC.                                                          




(mean ± SD) 
n = 6 + 6 
CV % F-testa Added (µg·mL−1) 
Measured 
(mean ± SD) 
n = 6 + 6 
CV % F-testa 
15.0 15.2 ± 0.2 1.3 3.773 0.7 0.4 ± 0.03 7.4 3.922 
30.0 30.8 ±0.5 1.8 0.045 1.5 0.9 ± 0.02 2.6 3.879 
60.0 61.7 ±0.6 1.0 4.041 3.0 2.5 ± 0.06 2.5 3.922 
aValue from table 4.960, α = 0.05. 
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Table 4. Recovery of cholesterol and 7-DHC.                                                                 
Cholesterol   7-DHC   
Concentration  
(µg·mL−1) 
Recovery (%) ± SD 
(n = 6) CV% 
Concentration  
(µg·mL−1) 
Recovery (%) ± SD 
(n = 6) CV% 
15.0 95.9 ± 1.8 1.8 0.7 65.1 ± 3.6 5.5 
30.0 93.8 ± 3.1 3.3 1.5 73.6 ± 2.1 2.8 
60.0 94.2 ± 2.6 2.7 3.0 79.7 ± 2.5 3.1 
 
Table 5. Stability of total cholesterol in amniotic fluids at +4˚C and +20˚C.                                         
 +4˚C  +20˚C  
Sample meana ± SD (n = 4) CV% meana ± SD (n = 4) CV% 
1 12.3 ± 0.3 2.5 12.3 ± 1.1 8.6 
2 8.7 ± 0.5 5.6 8.8 ± 0.5 5.6 
3 10.9 ± 1.2 11.2 10.1 ± 0.6 6.2 
aµg·mL−1. 
 
Table 6. Stability of total cholesterol derivatized at +4˚C and +20˚C.                                               
 +4˚C  +20˚C  
Sample meana ± SD (n = 4) CV% meana ± SD (n = 4) CV% 
1 12.5 ± 0.2 1.8 13.3 ± 0.1 1.1 
2 8.9 ± 0.3 3.1 8.7 ± 0.1 1.4 
3 11.3 ± 0.1 1.3 11.1 ± 0.1 1.1 
aµg·mL−1. 
 
species in the range of analysis of interest), even if a significant background noise was evidenced due to the 
pyridine employed in the derivatization protocol. 
Another important point assessed was the stability of the analytes either at 4˚C or at 20˚C, which is crucial 
because frequently it is not possible to analyse the amniotic fluids immediately after the withdrawal. In fact in 
many cases the fluids related to fetal growth retardations undergo preliminary genetic investigations. 
4.1. Control Amniotic Fluids 
39 amniotic fluids taken between the 14th and the 21th week of pregnancy from women whose age ranged from 
27 to 40 years were analysed. The cytogenetic analysis carried out on the amniocytes did not evidence any cy-
togenetic abnormalities, so these fluids were considered as control fluids. In these samples either the total con-
centration of cholesterol or the concentration of its free portion were determined (Table 7). It can be noted that 
there is not a significant variation in the concentration of cholesterol depending on the week of pregnancy, even 
if a lot of factors such as the age of the woman, the alimentary behaviour and the total volume of amniotic fluid 
could affect the level of this analyte. A particularly high value of total cholesterol was noticed in the sample 
taken at the 21th week, while at the 14th week this value was quite low. The determination of the free and total 
cholesterol in the control fluids evidenced a relatively constant value in particularly between the forth and the 
fifth month of pregnancy, the mean value of total and free cholesterol being respectively 10.3 µg mL−1 (SD ± 3.6) 
and 1.7 µg mL−1 (SD ± 0.91). 
4.2. Amniotic Fluids Related to Fetal Growth Retardation 
60 amniotic fluids taken from women showing a fetal growth retardation established by means of an echography 
evaluation were analyzed. The fetal growth retardation were divided into three classes: an overt intra uterine 
growth retardation (IUGR), a smaller fetus respect to the gestational age (SGA) and cases in which further bio-
medical studies were necessary (ACC). 
The quantitative determination of total cholesterol (it was not possible to determine its free portion because of 
the small amount of amniotic fluid available) was carried out by means of the GC/FID technique and the results 
V. Gambaro et al. 
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obtained are listed in Table 8. 
As it is evident, in the cases defined as IUGR, the mean concentration of cholesterol was significantly higher 
respect to the other cases. This phenomenon is probably related to the fact that in three samples the concentra-
tion of total cholesterol was superior to 100 µg/mL. These amniotic fluids were taken between the 24th and the 
25th week of pregnancy and it we could not establish if this high concentration was related to the gestational age 
or to other causes, because it was not possible to analyze control fluids of the same gestational age. The variabil-
ity of the total cholesterol concentration in the fluids in which a fetal growth retardation was established, was 
however higher than in the control fluids.  
Examining the GC chromatograms of the fluids related to a fetal growth retardation, in some of them a peak 
with a relative retention time (retention time of the analyte/retention time of the IS) of 0.95 was detected which 
corresponded neither to cholesterol (relative retention time 0.91) nor to 7-DHC (relative retention time 0.94). 
These samples were therefore investigated by means of the GC/MS technique, which allowed the identification 
of this peak as lathosterol [14], which is the precursor of 7-DHC in the biosynthesis of cholesterol. The identity 
of these compound was also confirmed comparing its chromatographic features and MS spectrum with those of 
a standard of lathosterol. The presence of this sterol was determined in 13 amniotic fluids related to a fetal 
growth retardation (Table 8). 
5. Conclusion 
A fast, reliable, sensitive and accurate GC/FID method was developed and validated for the determination of 
cholesterol and 7-DHC in amniotic fluids of women showing a fetal growth retardation potentially related to 
SLOS. The quantitative determination of cholesterol in control amniotic fluids evidenced that between the fourth 
and fifth month of pregnancy the levels of this analyte are quite constant, the concentration of total and free 
 
Table 7. Concentration of free and total cholesterol in the control amniotic fluids.                                    
   Free cholesterol 
(µg·mL−1) 
Total cholesterol 
(µg·mL−1)    
Weeks gestation n Range mother age Mean ± SD Range Mean ± SD Range 
14 4 32 - 38 1.3 ± 0.7 0.5 - 2.1 5.25 ± 1.1 3.6 - 6.7 
15 5 32 - 37 1.3 ± 0.1 1.1 - 1.5 11.4 ± 2.6 6.9 - 14.7 
16 9 29 - 41 1.7 ± 1.0 0.7 - 3.4 9.4 ± 2.4 4.8 - 13.8 
17 14 27 - 40 1.6 ± 9.6 1.1 - 3.3 10.9 ± 2.9 5.4 - 19.5 
18 2 35 3.3 ± 2.0 1.3 - 5.3 11.7 ± 4.0 7.7 - 15.7 
19 1 34 1.5 1.5 10.3 10.3 
20 3 27 - 34 1.9 ± 0.5 1.4 - 2.5 10.2 ± 1.3 8.3 - 11.5 
21 1 31 1.8 1.8 22.8 22.8 
  Total Total Total Total Total 
  27 - 41 1.7 ± 0.9 0.5 - 5.3 10.3 ± 3.6 3.6 - 22.8 
 
Table 8. Concentration of total cholesterol and lathosterol in the amniotic fluids related to a fetal growth retardation.         
   Total cholesterol (µg·mL−1) 
Fetal growth retardation n Weeks of pregnancy Mean ± SD Range 
IUGR 20 23 - 34 37.8 ± 47.9 4.9 - 154.6 
SGA 20 26 - 37 14.5 ± 7.2 4.6 - 30.5 
ACC 20 25 - 36 13.2 ± 13.1 5.1 - 65.1 
    
   Lathosterol (µg·mL−1) 
Fetal growth retardation n Weeks of pregnancy Mean ± SD Range 
IUGR 1 31 0.53 - 
SGA 8 26 - 37 0.73 ± 0.250 0.41 - 1.07 
ACC 4 25 - 33 0.90 ± 0.875 0.39 - 2.21 
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cholesterol being respectively 10.3 µg·mL−1 (SD = ±3.6) and 1.7 µg·mL−1 (SD = ±0.91). In the amniotic fluids 
related to fetal growth retardations, a higher variability of cholesterol amounts was found. Moreover in 13 sam-
ples an analyte which did not correspond neither to cholesterol nor to 7-DHC was detected. A GC/MS investiga-
tion allowed us to identify this compound as lathosterol, a precursor of cholesterol in the biosynthetic pathway. 
Unfortunately, it was not possible to establish a correlation between the levels of cholesterol and the presence of 
lathosterol with the possible presence of SLOS pathology in the newborns. In the future, the analytical method 
will be applied in order to investigate this correlation. 
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